MINNEAPOLIS, Oct. 16, 2013 /PRNewswire/ -- Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the U.S. Healthcare Product of the Year by Acquisition International (AI) for the remede® System, the first and only implantable device for the treatment of central sleep apnea. AI recognizes leaders in their fields for achievement and innovation.
"We are pleased to receive this award from Acquisition International and are grateful that the industry has recognized the value of the remedeSystem," said Tim Hauch, CFO of Respicardia. "This award acknowledges our efforts to develop a meaningful therapy and provide an innovative solution for cardiovascular disease patients with central sleep apnea."
The remede System has received CE mark in Europe and is currently being evaluated in an FDA approved pivotal trial at 25 centers in the U.S., with additional centers in Europe. Positive results from the pilot study evaluating the effects of the remede System were presented at the 2013 European Society of Cardiology (ESC) in Amsterdam, and in Late Breaking Clinical Trial session at the Heart Failure Society of America meeting held in Orlando, Florida last month.
About the Award:
Since 2010, Acquisition International's annual awards have been celebrating excellence, innovation and performance across the business, legal, financial and investment communities. AI's award winners are determined through a rigorous process, which starts by distributing ballot boxes and voting forms through industry partners. Votes are receivedalongside supporting evidenceand candidates are evaluated by AI's research team, to arrive at the final winners list. This comprehensive selection process ensures that awards are a valid representation of the market and that the winners are truly at the cutting edge of their fields.
About the remede® System:
The remede System is an implantable pacemaker-like device that was designed for improved respiratory rhythm management. The remede System delivers electrical pulses via an implantable lead to one of the body's two phrenic nerves. The diaphragm responds by restoring a more natural, less disrupted, breathing pattern.
About Central Sleep Apnea:
Central sleep apnea is a type of sleep-disordered breathing that disturbs the normal breathing pattern during sleep and adversely affects overall cardiovascular health. The disease occurs when the brain does not send the correct signals to the diaphragm and can lead to excessive daytime sleepiness, reduced exercise capacity, and irregular or very fast heart rhythms (arrhythmia). CSA affects up to 40% of heart failure patients and 30% of atrial fibrillation patients and is associated with the worsening of heart failure and an increased risk of death.
Founded in late 2006 and headquartered near Minneapolis, Minnesota, Respicardia is developing implantable therapies designed to improve respiratory and cardiovascular health. The company's initial product, the remede System, is an implantable stimulation device designed to restore a more regular breathing pattern during sleep for central sleep apnea patients.
For more information please visit www.respicardia.com.
SOURCE Respicardia, Inc.